Anaphylaxis — Viva Defence

Opening statement (SASPOP, delivered aloud)

“Ms Tran is a 29-year-old teacher with recurrent anaphylaxis — three episodes in 14 months, at least one severe and multi-dose, and two currently unexplained. Her main problems are: an unconfirmed trigger profile with probable idiopathic anaphylaxis; an unreliable safety net — she does not consistently carry her autoinjector; an unexamined cofactor and medication load; and the occupational and psychological consequences of unpredictable reactions in a woman responsible for a classroom. I would like to reconstruct every episode minutely, screen her for mast-cell disease, rebuild her safety net with device training and action plans for home and school, and refer her to an immunologist for definitive trigger work and consideration of prophylactic therapy.” [3] [4]

Structured problem list

1. Recurrent anaphylaxis, trigger incompletely defined — one attributed shellfish reaction never confirmed by testing; two unexplained episodes — idiopathic anaphylaxis is a diagnosis of exclusion and hides treatable causes [3].
2. Severity marker — one episode required two adrenaline doses and ICU observation; multi-dose and hypotensive reactions predict future severity and biphasic risk [5].
3. Safety-net failure — intermittent autoinjector carriage, no formal device retraining documented, no written action plan at work [4].
4. Unscreened for mast-cell and clonal disease — no baseline tryptase on record; recurrent unexplained reactions mandate it [2] [3].
5. Cofactors and comorbidity unreviewed — exercise, alcohol, NSAIDs, intercurrent infection, any ACE inhibitor or beta-blocker, asthma status [5].
6. Quality of life and occupation — food anxiety, avoidance behaviours, and the duty-of-care dimension of anaphylaxis risk in a teacher [4].

Integrated management plan

• Reconstruct each episode forensically: timeline of the preceding six hours — foods, alcohol, exercise, NSAIDs, illness, menstruation, insect exposure, new medications; obtain the ambulance and emergency records to grade each reaction objectively [1] [3].
• Baseline tryptase now (she is well beyond 24 hours from her last episode): a persistently elevated level redirects the case toward mastocytosis or hereditary alpha-tryptasaemia and triggers KIT D816V testing and haematology referral; the acute-versus-baseline delta framework also re-interprets her previous emergency samples [2] [3].
• Confirm or refute the shellfish attribution: specific IgE and skin-prick testing at least 4–6 weeks after the last reaction, interpreted against the history — testing without a compatible history manufactures false labels [4].
• Rebuild the safety net: two autoinjectors, hands-on training with teach-back today, a written ASCIA action plan for home and a school-specific plan with staff briefing, and medical-alert documentation [4].
• Control the amplifiers: twice-daily non-sedating antihistamine as background cover while the workup proceeds, asthma optimisation if relevant, explicit cofactor counselling — exercise and alcohol within hours of trigger foods, NSAID caution [3] [5].
• Immunology referral for definitive diagnosis and, if idiopathic anaphylaxis is confirmed and frequent, discussion of prophylactic options; venom immunotherapy is the model for disease modification when a venom trigger is found [6].

Probing questions with model answers

“Why do you not simply accept the shellfish label and move on?” — “Because two of her three episodes do not fit it, and a wrong label gives false reassurance in one direction and needless dietary restriction in the other. The attribution has never been tested; I will confirm or refute it with specific IgE and skin testing timed beyond the false-negative window, and in parallel I will hunt the real pattern in the two unexplained episodes” [4].

“Her tryptase during the ICU admission was normal. Does that change anything?” — “It weakens nothing on its own. Tryptase peaks at one to two hours and falls fast, food-triggered reactions often show no rise, and a single level without a baseline cannot be interpreted as a delta. I would check her baseline now — and if that baseline is elevated, the case becomes a mast-cell workup, not an allergy workup” [2] [3].

“She says she only carries the autoinjector 'when she remembers'. How do you respond?” — “With curiosity first, then structure. I would watch her actually use a trainer device — technique failure is common — then rebuild the habit: two devices, one with her and one at school, an action plan her colleagues have seen, and an honest conversation that her severe episode needed two doses, which is exactly the scenario a second device exists for” [4].

“What would make you chase a clonal mast-cell diagnosis?” — “A persistently elevated baseline tryptase, severe or unexplained recurrent episodes, reactions with prominent flushing and presyncope without urticaria, or stings provoking disproportionate collapse. The next steps are KIT D816V on peripheral blood, haematology referral, and bone-marrow assessment if indicated — the consensus criteria frame mast-cell activation as clinical features plus a biochemical rise plus response to mast-cell-directed therapy” [3].

“She asks: will the next one kill me?” — “Honesty with perspective: fatal anaphylaxis is rare, and the strongest predictors of a bad outcome are things we can modify — delayed adrenaline, uncontrolled cofactors, and not carrying the device. My job is to find the trigger if there is one, and to make sure that on her worst day, adrenaline reaches her thigh within minutes” [5].

Communication points

• Demonstrate the trainer device in the room and use teach-back — carrying is not competence [4].
• Co-design the school action plan — her colleagues are her first responders [4].
• Address food anxiety directly; over-restriction has its own morbidity, and unconfirmed labels should be tested, not obeyed [4].
• Set the follow-up contract: episode diary with cofactor fields, review after testing, and immunology linkage — recurrence should trigger plan revision, not just another emergency visit [3].